Viralytics' melanoma virotherapy hits PhII endpoint early
This article was originally published in Scrip
Executive Summary
Australian biotech company Viralytics has reported positive Phase II data for its lead product Cavatak (Coxsackievirus A21) in late-stage melanoma. Cavatak is an intratumoral oncolytic virus with the ability to bind to intercellular adhesion molecule 1 and decay-activating factor, which are overexpressed on certain cancer cells.